bryostatin-1


Also found in: Medical.

bryostatin-1

[¦brī·ə‚stat·ən ′wən]
(pharmacology)
A polyketide isolated from the bryozoan Bugula neritina that has both anticancer and immune modulating activity.
References in periodicals archive ?
These animal studies have indicated bryostatin-1 efficacy for restorative synaptogenesis, prevention of neuronal death, and anti-amyloid, anti-tau metabolism through the activation of PKC epsilon pathways via bryostatin-1 activation.
We provide evidence that Bryostatin-1 induce growth inhibition and apoptosis at nanomolar range consistently in T-cell derived human ALL cell line.
Recently data from our lab proposed a synthesis of bryostatin-1 from a precursor tentatively identified in the sediment of the Bugula ecosystem (20).
This Phase II, multicenter trial will study the effectiveness of bryostatin-1 plus cisplatin in treating patients who have recurrent or advanced cancer of the cervix.
We also showed that bryostatin-1 downregulates the expression of the HIV-1 receptors CD4 and CXCR4, and prevents HIV-1-induced cytotoxicity.
Neurotrope BioScience, a subsidiary of Neurotrope, has submitted an amended protocol for its Phase two clinical trial of lead candidate bryostatin-1 to the Food and Drug Administration, it was reported yesterday.
Our in vivo studies show that we can rapidly restore cognitive performance in AD-transgenic mice by oral administration of an oil-based formulation of Bryostatin-1.
Moving Bryostatin-1 from the lab to the clinic for the treatment of pulmonary hypertension:
It was reported on Tuesday that the company has been chosen to commence pre-patient enrolment activities to conduct a Phase IIb trial of its compound, bryostatin-1, to treat Alzheimer's disease.
Therapeutic candidates included in this analysis: AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999
It was reported yesterday that the contract has been signed to use the School of Medicine's information and data package for the development of Bryostatin-1 to treat Niemann-Pick Type C Disease.
In each company profile the data is divided according to several different sections and subsections:- General information - Collaborations and alliances - Drug development pipeline (drug name, indications, developmental stages, effects of drugs, mechanism of actions, targets, - combinatory treatments, general comments) - Related patents Some of the drugs included in the report:AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999